Abstract
Although mitochondrial dysfunction and reactive oxygen species (ROS) stress have long been observed in cancer cells, their role in promoting malignant cell behavior remains unclear. Here, we show that perturbation of the mitochondrial respiratory chain in breast cancer cells leads to a generation of subclones of cells with increased ROS, active proliferation, high cellular motility, and invasive behaviors in vitro and in vivo. Gene expression analysis using microarrays revealed that all subclones overexpressed CXCL14, a novel chemokine with undefined function. We further show that CXCL14 expression is up-regulated by ROS through the activator protein-1 signaling pathway and promotes cell motility through elevation of cytosolic Ca2+ by binding to the inositol 1,4,5-trisphosphate receptor on the endoplasmic reticulum. Abrogation of CXCL14 expression using a decoy approach suppressed cell motility and invasion. Our data suggest that mitochondrial dysfunction and ROS stress promote cancer cell motility through a novel pathway mediated by CXCL14.
Introduction
Emerging lines of evidence suggest that cancer cells may have mitochondrial dysfunction and adapt aerobic glycolysis to generate ATP. The involvement of reactive oxygen species (ROS) signaling in tumor metastasis has also been recognized (1, 2). ROS are constantly generated during cellular metabolism, particularly through the mitochondrial respiration, and exert various physiologic actions (3, 4). Oxidative stress is a state of redox imbalance caused by increased ROS generation, decreased antioxidant capacity, or both. Recent studies suggest that cancer cells, compared with the normal cells, are under increased oxidative stress associated with oncogenic transformation, alterations in metabolic activity, and increased generation of ROS (5–7). The increased ROS in cancer cells may in turn affect certain redox-sensitive molecules and further lead to significant consequences such as stimulation of cellular proliferation, cell differentiation, alterations in sensitivity to anticancer agents, promotion of mutations and genetic instability, and contributing to carcinogenesis (5, 8–11). The accumulation of certain genomic mutations enables cells to further acquire the ability to proliferate, generate a tumor, and eventually metastasize (12).
Mitochondria are major sites of ROS generation, which occurs mainly at complexes I and III of the respiratory chain. ROS production increases when electron transport function is compromised, leading to increased leakage of electrons, which react with oxygen to form superoxide. The molecular mechanisms involved in the mitochondrial dysfunction and increased ROS production are not well understood. Multiple pathways may converge in mitochondria to modify respiratory chain activity. Moreover, recent studies indicate that the production of ROS may be accompanied by changes in mitochondrial metabolism (13). The production of excess superoxide can cause oxidative DNA damage and genomic instability (14), transformation of cells in culture (8), and potentiate tumor progression (11). In fact, mitochondrial DNA (mtDNA) is highly susceptible to damage because it is not protected by histones and is directly exposed to ROS generated by the respiratory chain. Moreover, DNA repair capacity is less efficient in the mitochondria. These factors might explain why human cancers have high levels of mtDNA mutations.
Since Warburg proposed the cancer “respiration injury” theory (15), mitochondrial alterations in cancer cells have been intensively studied to understand their role in tumor development, ROS generation, and carcinogenesis (16, 17). Despite significant progress in this research area, little is known of the alterations in mitochondrial structure and function that contribute to cell mobility and metastasis, especially in breast cancer cells. Here we report that perturbation of mitochondrial respiration in breast cancer cells leads to redox alterations and more invasive behaviors, which seem to be mediated by elevated cytosolic calcium through a novel ROS→activator protein-1 (AP-1)→CXCL14 pathway.
Materials and Methods
Reagents
[3H]Deoxyglucose and [γ-32P]ATP were acquired from Amersham Pharmacia Biotech. Recombinant human active CXCL14 and CXCL14 antibody were obtained from R&D Systems. GRP78 and heat shock protein 60 antibodies were from Santa Cruz Biotechnology, Inc., and inositol 1,4,5-triphosphate receptor (IP3R) antibody from BD Biosciences. SP600125 was acquired from AG Scientific, Inc. CM-H2DCF-DA, dihydroethidium (Het), Calcium Green-1, MitoTracker Green, Fluo-3, ER-Tracker Blue-White DPX, rhodamine-123, and ionomycin were purchased from Invitrogen/Molecular Probes. Phosphorothioate decoy oligo specific for AP-1 (5′-CACTCGGTGACTCACTGAGATTTAAAAAAAATCTCAGTGAGTCACCGAGTGGTTCTGCATA-3′) and phosphorothioate scrambled oligo (5′-GCATGGACTGTATCGGAAAAACGATACAGTCCATGCCATTATA-3′) were synthesized by Sigma Genosys. The 2 bases at the 3′ and 5′ ends are phosphorothioates. Human CXCL14 cDNA clone was from Origene Technologies, Inc.
Cell culture and migration/invasion assays
MCF7 and its subclones were cultured in DMEM-F12 medium (Cellgro, Mediatech, Inc.) supplemented with 10% fetal bovine serum and 2 mmol/L glutamine at 37°C with 5% CO2. Cell migration and invasion assays were done using chambers with 8-µm-porosity polycarbonate filter membranes according to the manufacturer’s instructions (Becton Dickinson Labware). Cells that invaded to the lower surface were stained with Fisher Diagnostics Hema 3 Staining System (Thermo Fisher Scientific, Inc.) and photographed under a microscope (Eclipse TS100, Nikon) at ×20 magnification.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation assay kit from Upstate was used for this study. Protein-DNA complexes were immunoprecipitated with AP-1 antibody (Santa Cruz Biotechnology). PCR was done using 2 AL of DNA sample with primers 5′-GGCGACGGGCGGGCTGGGAAG-3′ ( forward) and5′-GGAGACGCCACCCAGCTCTG-3′ (reverse) to amplify region −323/−83 of the CXCL14 promoter. Amplification of soluble DNA before immunoprecipitation was used as an input control. All chromatin immunoprecipitation experiments were repeated at least three times.
Measurements of respiration, glucose uptake, lactate production, ROS, mitochondrial mass, mitochondrial membrane potential, and calcium
Oxygen consumption, cellular glucose uptake, lactate production, mitochondria mass, ROS content, and mitochondrial transmembrane potential (Δψm) were measured as previously described (18, 19). To measure cellular Ca2+, cells were stained with 3 µmol/L Calcium Green-1 in serum-free medium for up to 1 h and analyzed using a FACScan flow cytometer (Becton Dickinson Bioscience). Cells were loaded with 200 nmol/L ER-Tracker Blue-White DPX to measure endoplasmic reticulum (ER) Ca2+ under UV excitation, using a LSRII flow cytometer (Becton Dickinson) equipped with a 350-nm excitation laser and a 530-nm centered band-pass filter, as previously described (20).
Nuclear extract and gel shift assay
EMSA analysis was done using the Gel Shift Assay System (Promega), according to the manufacturer’s instructions, with human recombinant AP-1 (c-jun) and 5 µg of nuclear extracts from MCF7 cells, and subclones were prepared as previously described (21)
RNA isolation and reverse transcription-PCR analyses
RNA was isolated from MCF7 cells and its subclones using the RNeasy kit and reverse transcribed using the Omniscript RT kit (Qiagen) according to the manufacturer’s instructions. The amplification primers for CXCL14 were 5′-GTCCAAATGCAAGTGCTCCC-3′ (forward) and 5′-TTCTTCGTAGACCCTGCGCT-3′ (reverse), and for β-actin were 5′-GCATCGTCACCAACTGGGAC-3′ (forward) and 5′-ACCTGGCCGTCAGGCAGCTC-3′ (reverse). cDNA was amplified using standard PCR conditions.
Subcellular fractionation and microsome Ca2+ release assay
Mitochondria and ER were isolated from cells as previously described (22). Microsomes from MCF7 cells were isolated using an Endoplasmic Reticulum Isolation kit according to the manufacturer’s instructions (Sigma) and used immediately to assay Ca2+ release as described by Guillemette and colleagues (23).
Measurement of Ca2+ influx in whole cells
Cells were loaded for 1 h with 5 µmol/L Fluo-3-AM (1 × 106 cells/mL) in Ca2+-free HBSS buffer containing 1% bovine serum albumin. Then, cells were washed twice with HBSS and resuspended in HBSS containing 2 mmol/L Ca2+. Ca2+ influx was measured by flow cytometry and triggered by the addition of 2 µmol/L thapsigargin after 10 s. To ensure proper loading, Ca2+ influx from each cell line was stimulated with 2 µmol/L ionomycin. Analysis was done using a FACScan flow cytometer (Becton Dickinson), and the kinetic analysis of Fluo-3 versus time as the mean value of individual cells was done using FlowJo software (Tree Star, Inc.).
Animal studies
Six-week-old female BABL/c nude mice were inoculated on the mammary fat pads with MCF7 or its subclones. In both cases, 2 × 106 cells were combined with 100 µL of DMEM-F12 and Matrigel (1:1; BD Biosciences). Mice were inspected daily, and their well-being and body weight monitored. Moribund animals were euthanized as mandated by the Institutional Animal Care and Use Committee (IACUC) protocol, and the time of death was recorded. Tumor tissues from representative mice were sectioned, embedded in paraffin, and stained with H&E for histopathologic evaluation.
Statistical analysis
Student’s t test was used to evaluate the statistical differences between the experimental values of two samples being compared. P < 0.05 was considered statistically significant.
Results
Generation and characterization of MCF7 subclones with aggressive cellular behaviors
To study the role of mitochondrial dysfunction in invasion, we developed an experimental system using human breast cancer MCF7 cells, which can form localized tumors in nude mice with estrogen supplement but are weakly metastatic. Because electron leakage from the mitochondrial respiratory chain is a major source of ROS, we hypothesized that a disruption of mitochondrial respiration would increase ROS, which may promote genetic instability and the emergence of more aggressive malignant cells. As illustrated in Fig. 1A, we used rotenone, an inhibitor of the electron transport complex I known to promote superoxide generation (18), to induce ROS stress in MCF7 cells. After three cycles of rotenone treatment, the cells were plated in drug-free medium to allow the formation of colonies. Among 16 clones picked, two clones (H and P) with high ROS and active cell migration were selected for further studies. Figure 1B shows the representative ROS levels. Interestingly, the increased ROS in these clones persisted for at least 6 months without rotenone, likely reflecting persistent mitochondrial dysfunction. In fact, both H and P clones still exhibited reduced mitochondrial respiration, as indicated by a decrease in oxygen consumption (Fig. 1C) and a compensatory increase in glycolysis, as indicated by higher glucose uptake and lactate production (Fig. 1C). Analysis of cellular ATP showed that both clones had similar cellular ATP compared with the parental MCF7 cells (Supplementary Fig. S1), suggesting that the up-regulation of glycolysis was sufficient to compensate the decreased ATP generation in the mitochondria. Consistently, the subclones exhibited a slight increase in their mitochondrial mass with similar transmembrane potential (Fig. 1D). The subclones showed similar or slightly higher proliferation (Fig. 1D, right). These results are consistent with the previous observations that increased mitochondrial mass and mtDNA contents are early molecular events in response to endogenous oxidative stress (24).
Because ROS can alter gene expression (10, 25) and stimulate cell invasiveness (26), we tested the motility and invasive potential of the subclones. A wound healing assay showed that H and P clones exhibited a higher capacity to migrate and fill the gap in culture compared with MCF7 (Fig. 2A). To evaluate whether the increase in ROS in H and P clones was essential for this process, cells were pretreated with the antioxidant N-acetyl cysteine (NAC) before the wound healing assay. NAC effectively inhibited cell motility (Fig. 2A). We also isolated several clones from MCF7 cells without treatment with rotenone as control. No significant change in motility was observed (Supplementary Fig. S2). Subclones H and P exhibited significantly greater ability than the parental MCF7 cells to migrate through a layer of matrix gel and pass membrane pores (Fig. 2B and C). Furthermore, colony formation assay in soft agar showed similar or slightly higher anchorage-independent colony-forming rates (number of colonies per well) in the subclones, but the size of each colony was smaller than those of MCF7 cells (Supplementary Fig. S3).
We then tested the ability of clones P and H and the parental MCF7 cells to form tumors in vivo. Parental MCF7 cells and P and H clones were inoculated on the mammary fat pads of 6-week-old BABL/c nude mice. Both the P and H clones formed palpable tumors in the absence of exogenous estrogen, whereas the parental MCF7 cells exhibited poor ability to form tumors under these conditions. Three of the five mice inoculated with P clone cells exhibited extensive metastasis to liver, lung, and spleen. The histologic morphology of the primary and metastatic tumors is shown in Fig. 2D. No metastasis was detected in the mice inoculated with H clone cells by the time when the primary tumor reached the maximal size requiring euthanasia, as mandated by the IACUC-approved protocol. No metastasis was observed in mice inoculated with the parental MCF7 cells.
ROS promotes CXCL14 expression in MCF7 subclone cells through activation of AP-1
To elucidate the mechanisms by which mitochondrial dysfunction alters cell migration/invasion, we performed microarray analysis of gene expression in several clones of cells with increased ROS. We observed that the expression of CXCL14, a novel chemokine, was significantly elevated in all clones tested in comparison with MCF7 cells. The overexpression of CXCL14 in clones P and H was confirmed by reverse transcription-PCR (RT-PCR) and Western blotting (Fig. 3A). The ability of CXCL14 to stimulate cell migration was then tested using the wound healing assay. Figure 3B shows that recombinant CXCL14 protein (0.57 ng/mL) significantly enhanced MCF7 cell migration. Furthermore, conditioned medium from clones P and H also promoted cell migration (Fig. 3B). Ectopic overexpression of CXCL14 in MCF7 cells by transfection also rendered the cells highly migratory (Fig. 3C). To further evaluate the relationship between the induction of CXCL14 and increased migration and invasion, we used a decoy strategy using a synthetic double-stranded phosphorothioate oligonucleotide, which contained a hairpin structure resembling the CXCL14 promoter region and functioned as a cis-element to suppress CXCL14 expression. Transfection of H clone with the decoy DNA efficiently suppressed CXCL14 transcription and inhibited cellular migration, as evidenced by the reduced numbers of cells migrating through the membrane (Fig. 3D).
We then used an antioxidant to investigate whether ROS regulate CXCL14 expression. NAC partially suppressed the expression of CXCL14 in clone P (Fig. 4A, bottom) and clone H (data not shown), suggesting that CXCL14 expression might be regulated by ROS. Consistently, hydrogen peroxide (H2O2) promoted CXCL14 expression in a time- and dose-dependent manner (Fig. 4A, top). Interestingly, another clone with slower proliferation rate (clone D) also exhibited increase ROS generation, higher CXCL14 expression, and active cell motility (Supplementary Fig. S4). Thus, the increase in cell motility was correlated with ROS generation and CXCL14 expression and was not due to active proliferation.
To further explore the mechanism by which ROS regulate CXCL14 expression, we performed a gene database analysis and identified a potential AP-1 binding sequence within the putative promoter region of CXCL14. EMSA assay using a radioactively labeled oligonucleotide containing the AP-1 consensus sequence showed that both subclones (H and P) had an increase in AP-1 activity compared with the parental cells (Fig. 4B, left). Furthermore, nuclear extract from MCF7 cells exposed to H2O2 for 20 minutes showed a significant increase in AP-1 DNA binding (Fig. 4B, right), suggesting a role of ROS in regulating CXCL14 expression through AP-1. To test this possibility, the CXCL14-overexpressing cells (clone H) were incubated with the c-Jun-NH2-kinase (JNK) inhibitor SP600125 to block c-Jun (a component of AP-1) activation and then tested if this would cause a decrease of CXCL14 transcription. Indeed, SP600125 inhibited AP-1 DNA binding and reduced CXCL14 expression at the mRNA and protein levels (Fig. 4C). Chromatin immunoprecipitation was then used to analyze if AP-1 binds to CXCL14 promoter. As shown in Fig. 4D, after protein-DNA cross-linking, immunoprecipitation with AP-1 antibody pulled down the CXCL14 promoter DNA sequence, which was detected by PCR using specific primers spanning the −323 to −83 region of the human CXCL14 promoter. These results show that AP-1 binds to CXCL14 promoter.
CXCL14 induced an increase in cellular Ca2+ through interaction with IP3R
Because Ca2+ plays an essential role in cell motility and the ER is a major regulator of cellular Ca2+ homeostasis (27), we tested if CXCL14 affects ER function and alters cytosolic Ca2+ in the subclones. Using subcellular fractionations, we found that CXCL14 was significantly higher in the ER compartments of clones H and P than MCF7 cells (Fig. 5A). Interestingly, analysis of cytosolic Ca2+ revealed that clones H and P had significantly higher cytosolic Ca2+ contents than the parental MCF7 cells (Fig. 5B, left), whereas the ER Ca2+ levels were significantly lower in clones H and P (Fig. 5B, right). This suggests a possible “leakage” of Ca2+ from the ER to the cytosol associated with the localization of CXCL14 to ER. Transfection of MCF7 cells with CXCL14 caused an increase in cytosolic Ca2+ (Fig. 5C). Because the IP3R of ER plays an important role in Ca2+ signaling via interaction with inositol 1,4,5-trisphosphate (IP3; ref. 28), we examined whether CXCL14 binds to IP3R and disturbs its function. Immunoprecipitation with IP3R antibody and Western blotting of the pulled-down products using anti-CXCL14 showed a physical association between CXCL14 and IP3R (Fig. 5D). We reasoned that if the binding of CXCL14 to IP3R caused a leak of Ca2+ from the ER to the cytosol, the amount of Ca2+ stored in the ER would be lower in the subclones than in the parental MCF7 cells and that a release of ER Ca 2+ into the cytosol triggered by thapsigargin would cause less increase of cytosolic Ca2+ in the subclones. As shown in Fig. 6A, thapsigargin caused a rapid increase of cytosolic Ca2+ in MCF7 cells and a substantially smaller Ca2+ increase in the P clone cells, suggesting lower ER Ca2+ storage in P cells. The effect of thapsigargin on Ca2+ levels in these cells was further investigated in the presence of 100 µmol/L 2-aminoethoxydiphenyl borate (2-APB), a compound that blocks receptor-induced Ca2+ store emptying (29). Preincubation of MCF7 cells with 2-APB almost completely suppressed thapsigargin-induced Ca2+ release in MCF7 cells, but this effect was substantially attenuated in clone P (Fig. 6A). Thus, CXCL14 might interact with the 2-APB–sensitive domain of IP3R, leading to Ca2+ leakage and a blunted response to thapsigargin.
To directly test the role of CXCL14 on Ca2+ flux regulation in the ER, we isolated the ER fraction from MCF7 cells and measured Ca2+ release from the ER microsomes in the presence and absence of purified CXCL14 protein. As shown in Fig. 6B to D, CXCL14 induced Ca2+ release from the ER microsomes in a time- and dose-dependent manner. As a positive control, Ca2+ release was triggered by 10 µmol/L IP3 to activate IP3R or by 10 µmol/L thapsigargin to inhibit the ER Ca2+ pump. As expected, IP3 and thapsigargin caused a dramatic Ca2+ release, whereas CXCL14 induced a moderate but consistent Ca2+ release (Fig. 6D). This may explain why overexpression of CXCL14 led to a moderate and sustained increase in cytosolic Ca2+ without causing cytotoxicity.
Discussion
Breast cancer metastasis represents a major challenge in clinical treatment of this disease, and the detailed mechanisms that regulate breast cancer cell motility and metastasis remain to be an important research area. It is known that mitochondria are major sites of ROS generation in the cells and that ROS can function as signaling molecules to stimulate cell proliferation and promote cell motility (1). Interestingly, mitochondria dysfunction has been shown to contribute to tumor progression by enhancing the metastatic potential of tumor cells (30). However, the mechanism by which ROS stimulates cell motility is still unclear. The present study provides several lines of evidence suggesting that increased expression of CXCL14 may play an important role in this process. (a) Both clones H and P, which were isolated after chemical disruption of the mitochondrial respiration in MCF7 cells, exhibit increased ROS, cellular motility, and ability to invade through Matrigel. These malignant behaviors were suppressed by the antioxidant NAC, indicating the important role of ROS, which was associated with mitochondrial dysfunction. (b) CXCL14 was overexpressed in both H and P clones, and this expression was stimulated by exogenous ROS and suppressed by NAC. (c) The role of CXCL14 in promoting cell migration and invasion was shown by direct stimulation of cell motility using recombinant CXCL14 protein, conditional medium, or overexpression of CXCL14 through gene transfection. (d) CXCL14 caused Ca2+ leakage from the ER through binding to IP3R, leading to increased cytosolic Ca2+. (e) ROS seem to induce CXCL14 expression through activation of the AP-1 pathway, as shown by specific decoy DNA, JNK inhibitor, and antioxidant.
CXCL14 (also known as BRAK or MIP-2γ) is a chemokine with yet unknown function (31, 32). This molecule was first identified by differential display using normal epithelial cells and head and neck squamous carcinoma cells and was shown to be expressed in normal epithelial tissues and in various tumors of epithelial origin with heterogeneous expression levels (31, 33). The receptor for CXCL14 has not yet been identified, and conflicting biological functions of this molecule are described in the literature (34–37). CXCL14 is associated with the development and progression of breast cancer, and its gene expression level is correlated with the clinical metastases time of breast cancer patients (38). Moreover, CXCL14 seems to increase the invasiveness of pancreatic cancer cells by activation of the nuclear factor-κB pathway (39). Our study suggests that in breast cancer cells, CXCL14 promotes cell motility through its ability to induce release of Ca2+ to the cytosol.
CXCL14 seems to provide a molecular link between ROS stress and increased cell motility. DNA analysis revealed that the CXCL14 putative promoter region contains a binding site for AP-1, a transcription regulatory complex known to be redox sensitive. We showed that inhibition of JNK by SP600125 suppressed AP-1 DNA binding activity and reduced CXCL14 expression. The AP-1 decoy also suppressed CXCL14 expression and inhibited cell motility. Thus, activation of AP-1 is a likely mechanism for ROS-induced CXCL14 up-regulation. Interestingly, metastatic breast carcinoma cells (estrogen receptor negative) have higher AP-1 DNA binding activity than do less metastatic carcinomas (estrogen receptor positive), and expression of Fra-1 correlates with AP-1 activity and invasiveness in these cells (40). Several AP-1–responsive genes with roles in facilitating the invasion of malignant cells have been described (41, 42), and our study suggests that CXCL14 is another important AP-1 effector. Our observations that mitochondrial dysfunction induces ROS-mediated AP-1 activation and CXCL14 up-regulation is consistent with a recent study that mitochondrial oxidative stress through overproduction of H2O2 induced the Jun kinase pathway (13).
Calcium plays an essential role in the assembly of actin filaments and cytoskeleton reorganization and, thus, affects cell motility and migration. We found that cytosolic Ca2+ levels in both clones H and P were elevated. This increase in cytosolic Ca2+ is likely due to the release of Ca2+ from the ER. We showed that CXCL14 was present in the ER, physically interacted with IP3R, and directly induced Ca2+ release from isolated ER microsomes. Furthermore, the IP3R inhibitor 2-APB was significantly less effective in preventing thapsigargin-induced Ca2+ mobilization in CXCL14-overexpressing clone P cells than in the parental MCF7 cells. Together, these observations suggest that CXCL14 induces cytosolic Ca2+ increase by mobilization of Ca2+ from the ER through binding to IP3R, and that CXCL14 might attenuate the function of 2-APB–sensitive IP3R channels. In future study, it would be interesting to further determine the detailed molecular interaction between CXCL14 and IP3R through systemic deletion of the CXCL14 peptide segments to identify the interface responsible for binding, and use specific antibodies to show the colocalization of the two molecules on the ER membranes.
Although a high level of cytosolic Ca2+ can stimulate mitochondrial respiration in cells with competent mitochondrial, this may not happen in cells with compromised mitochondrial function. In our experimental system, the Ca2+ increase seemed to be a consequence of mitochondria dysfunction initially induced by rotenone. It is unclear if the increased cytosolic Ca2+ may play a role in up-regulation of glycolysis. Interestingly, most glycolytic enzymes bind to cytoskeleton, and it is possible that increased cytosolic Ca2+ might promote the assembly of cytoskeleton-bound glycolytic enzymes leading to high glycolytic activity.
Of note, the aggressive malignant cell behaviors of the clones H and P were stable after the cells were cultured in medium free of rotenone, suggesting a possibility that the initial ROS increase induced by rotenone might have induced mutations in mtDNA or/and nuclear DNA. We have attempted to identify mtDNA mutations by direct sequencing of mtDNA for these two subclones in comparison with the parental MCF7 cells. No mtDNA mutation was detected. It is possible that in clones H and P, mutation(s) might have occurred in the nuclear DNA at a gene that affects mitochondrial function leading to decreased respiration and increased glycolysis, which seemed to affect cell proliferation and colony formation in a complex manner: high colony number but smaller colony sizes. Although the exact reason for such complex growth alterations remain unclear, this phenomenon may explain why the subclones showed similar overall cell growth curves compared with the parental MCF7 cells, as measured by direct counting of cell number (Fig. 1D, right).
In conclusion, our findings suggest that mitochondrial dysfunction in human breast cancer cells can promote cell motility and invasive behaviors through the AP-1/CXCL14/calcium pathway. The increased ROS in cancer may promote cellular proliferation and migration leading to more aggressive malignant behaviors and metastasis. It should be pointed out, however, that because elevated ROS may also cause cellular damage and induce senescence, only those cancer cells capable of mobilizing their antioxidant systems and other regulatory mechanisms to effectively counteract the adverse effects of ROS can reestablish redox balance and emerge as highly malignant clones. In fact, we observed that the cancer cells with high ROS generation in long-term culture tended to rebalance their ROS generation and elimination, leading to a steady redox state that favored their continuous proliferation in culture. Thus, ROS signaling and its roles in cancer development and metastasis are extremely complex biological processes. Understanding these mechanisms is essential for developing new therapeutic strategies to effectively inhibit cancer growth and prevent metastasis.
Supplementary Material
Acknowledgments
Grant support: National Cancer Institute grants CA85563, CA109041, CA100428, CA100632, and CA16672.
We thank Wendy D. Schober and K. Dwyer for flow cytometry analysis and Kenneth Dunner, Jr. for assistance in the transmission electron microscopy studies.
Footnotes
Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
References
- 1.Storz P. Reactive oxygen species in tumor progression. Front Biosci. 2005;10:1881–1896. doi: 10.2741/1667. [DOI] [PubMed] [Google Scholar]
- 2.Radisky DC, Levy DD, Littlepage LE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature. 2005;436:123–127. doi: 10.1038/nature03688. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Ristow M. Oxidative metabolism in cancer growth. Curr Opin Clin Nutr Metab Care. 2006;9:339–345. doi: 10.1097/01.mco.0000232892.43921.98. [DOI] [PubMed] [Google Scholar]
- 4.Wu M, Neilson A, Swift AL, et al. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol. 2007;292:C125–C136. doi: 10.1152/ajpcell.00247.2006. [DOI] [PubMed] [Google Scholar]
- 5.Pelicano H, Carney D, Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 2004;7:97–110. doi: 10.1016/j.drup.2004.01.004. [DOI] [PubMed] [Google Scholar]
- 6.Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25:4633–4646. doi: 10.1038/sj.onc.1209597. [DOI] [PubMed] [Google Scholar]
- 7.Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E. Energy metabolism in tumor cells. FEBS J. 2007;274:1393–1418. doi: 10.1111/j.1742-4658.2007.05686.x. [DOI] [PubMed] [Google Scholar]
- 8.Suh YA, Arnold RS, Lassegue B, et al. Cell transformation by the superoxide-generating oxidase Mox1. Nature. 1999;401:79–82. doi: 10.1038/43459. [DOI] [PubMed] [Google Scholar]
- 9.Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature. 2000;407:309–311. doi: 10.1038/35030140. [DOI] [PubMed] [Google Scholar]
- 10.Droge W. Free radicals in the physiological control of cell function. Physiol Rev. 2002;82:47–95. doi: 10.1152/physrev.00018.2001. [DOI] [PubMed] [Google Scholar]
- 11.Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol. 2004;44:239–267. doi: 10.1146/annurev.pharmtox.44.101802.121851. [DOI] [PubMed] [Google Scholar]
- 12.Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. doi: 10.1016/s0092-8674(00)81683-9. [DOI] [PubMed] [Google Scholar]
- 13.Nemoto S, Takeda K, Yu ZX, Ferrans VJ, Finkel T. Role for mitochondrial oxidants as regulators of cellular metabolism. Mol Cell Biol. 2000;20:7311–7318. doi: 10.1128/mcb.20.19.7311-7318.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Samper E, Nicholls DG, Melov S. Mitochondrial oxidative stress causes chromosomal instability of mouse embryonic fibroblasts. Aging Cell. 2003;2:277–285. doi: 10.1046/j.1474-9728.2003.00062.x. [DOI] [PubMed] [Google Scholar]
- 15.Warburg O. On the origin of cancer cells. Science. 1956;123:309–314. doi: 10.1126/science.123.3191.309. [DOI] [PubMed] [Google Scholar]
- 16.Alirol E, Martinou JC. Mitochondria and cancer: is there a morphological connection? Oncogene. 2006;25:4706–4716. doi: 10.1038/sj.onc.1209600. [DOI] [PubMed] [Google Scholar]
- 17.Chatterjee A, Mambo E, Sidransky D. Mitochondrial DNA mutations in human cancer. Oncogene. 2006;25:4663–4674. doi: 10.1038/sj.onc.1209604. [DOI] [PubMed] [Google Scholar]
- 18.Pelicano H, Feng L, Zhou Y, et al. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem. 2003;278:37832–37839. doi: 10.1074/jbc.M301546200. [DOI] [PubMed] [Google Scholar]
- 19.Xu RH, Pelicano H, Zhou Y, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005;65:613–621. [PubMed] [Google Scholar]
- 20.Robinson JP, Darzynkiewicz Z, Dean PN, et al. Current protocols in cytometry. New York: John Wiley & Sons, Inc.; 2000. [Google Scholar]
- 21.Pines A, Perrone L, Bivi N, et al. Activation of APE1/Ref-1 is dependent on reactive oxygen species generated after purinergic receptor stimulation by ATP. Nucleic Acids Res. 2005;33:4379–4394. doi: 10.1093/nar/gki751. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Morimoto T, Sabatini DD, Doda JN. Subcellular fractionation. In: Spector DL, Goldman RD, Leinwand LA, editors. Cells: a laboratory manual, culture of cells and biochemical analysis. New York: Cold Spring Harbor Laboratory; 1998. pp. 34.1–41.4. [Google Scholar]
- 23.Guillemette G, Balla T, Baukal AJ, Catt KJ. Characterization of inositol 1,4,5-trisphosphate receptors and calcium mobilization in a hepatic plasma membrane fraction. J Biol Chem. 1988;263:4541–4548. [PubMed] [Google Scholar]
- 24.Lee HC, Yin PH, Lu CY, Chi CW, Wei YH. Increase of mitochondria and mitochondrial DNA in response to oxidative stress in human cells. Biochem J. 2000;348:425–432. [PMC free article] [PubMed] [Google Scholar]
- 25.Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol. 2003;15:247–254. doi: 10.1016/s0955-0674(03)00002-4. [DOI] [PubMed] [Google Scholar]
- 26.Mori K, Shibanuma M, Nose K. Invasive potential induced under long-term oxidative stress in mammary epithelial cells. Cancer Res. 2004;64:7464–7472. doi: 10.1158/0008-5472.CAN-04-1725. [DOI] [PubMed] [Google Scholar]
- 27.Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4:517–529. doi: 10.1038/nrm1155. [DOI] [PubMed] [Google Scholar]
- 28.Berridge MJ. Elementary and global aspects of calcium signalling. J Physiol. 1997;499:291–306. doi: 10.1113/jphysiol.1997.sp021927. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Maruyama T, Kanaji T, Nakade S, Kanno T, Mikoshiba K. 2APB, 2-aminoethoxydiphenyl borate, a membrane-penetrable modulator of Ins(1,4,5)P3-induced Ca2+ release. J Biochem (Tokyo) 1997;122:498–505. doi: 10.1093/oxfordjournals.jbchem.a021780. [DOI] [PubMed] [Google Scholar]
- 30.Ishikawa K, Takenaga K, Akimoto M, et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science. 2008;320:661–664. doi: 10.1126/science.1156906. [DOI] [PubMed] [Google Scholar]
- 31.Frederick MJ, Henderson Y, Xu X, et al. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol. 2000;156:1937–1950. doi: 10.1016/S0002-9440(10)65067-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Hromas R, Broxmeyer HE, Kim C, et al. Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem Biophys Res Commun. 1999;255:703–706. doi: 10.1006/bbrc.1999.0257. [DOI] [PubMed] [Google Scholar]
- 33.Schwarze SR, Luo J, Isaacs WB, Jarrard DF. Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate. 2005;64:67–74. doi: 10.1002/pros.20215. [DOI] [PubMed] [Google Scholar]
- 34.Kurth I, Willimann K, Schaerli P, Hunziker T, Clark-Lewis I, Moser B. Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J Exp Med. 2001;194:855–861. doi: 10.1084/jem.194.6.855. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Shellenberger TD, Wang M, Gujrati M, et al. BRAK/CXCL14 is a potent inhibitor of angiogenesis and is a chemotactic factor for immature dendritic cells. Cancer Res. 2004;64:8262–8270. doi: 10.1158/0008-5472.CAN-04-2056. [DOI] [PubMed] [Google Scholar]
- 36.Shurin GV, Ferris RL, Tourkova IL, et al. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol. 2005;174:5490–5498. doi: 10.4049/jimmunol.174.9.5490. [DOI] [PubMed] [Google Scholar]
- 37.Allinen M, Beroukhim R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6:17–32. doi: 10.1016/j.ccr.2004.06.010. [DOI] [PubMed] [Google Scholar]
- 38.Chiu SH, Chen CC, Lin TH. Using support vector regression to model the correlation between the clinical metastases time and gene expression profile for breast cancer. Artif Intell Med. 2008;44:221–231. doi: 10.1016/j.artmed.2008.06.005. [DOI] [PubMed] [Google Scholar]
- 39.Wente MN, Mayer C, Gaida MM, et al. CXCL14 expression and potential function in pancreatic cancer. Cancer Lett. 2008;259:209–217. doi: 10.1016/j.canlet.2007.10.021. [DOI] [PubMed] [Google Scholar]
- 40.Philips A, Teyssier C, Galtier F, et al. FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells. Mol Endocrinol. 1998;12:973–985. doi: 10.1210/mend.12.7.0133. [DOI] [PubMed] [Google Scholar]
- 41.Crowe DL, Tsang KJ, Shemirani B. Jun N-terminal kinase 1 mediates transcriptional induction of matrix metalloproteinase 9 expression. Neoplasia. 2001;3:27–32. doi: 10.1038/sj.neo.7900135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Vleugel MM, Greijer E, Bos R, van der Wall E, van Diest PJ. c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum Pathol. 2006;37:668–674. doi: 10.1016/j.humpath.2006.01.022. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.